Dilantin® Toxicity: Miliary Pulmonary Infiltrates and Hypoxemia

Letters1 October 1976Dilantin® Toxicity: Miliary Pulmonary Infiltrates and HypoxemiaARNOLD S. BAYER, M.D., STEPHAN R. TARGAN, M.D., HOWARD E. PITCHON, M.D., LUCIEN B. GUZE, M.D., F.A.C.P.ARNOLD S. BAYER, M.D.Search for more papers by this author, STEPHAN R. TARGAN, M.D.Search for more papers by this author, HOWARD E. PITCHON, M.D.Search for more papers by this author, LUCIEN B. GUZE, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-85-4-475 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptA number of serious adverse effects have been reported in association with diphenylhydantoin (Dilantin®) therapy ( 1 ), including hepatitis, pancytopenia, and purpura fulminans. Although morbidity from these reactions can be significant, Dilantin toxicities are usually not life-threatening. We recently saw a patient who developed miliary chest infiltrates and severe hypoxemia with Dilantin treatment. In addition, extensive dermatitis and hepatitis were observed. Since serious pulmonary reactions to Dilantin have been infrequently cited, we report this unusual case.A 47-year-old man was admitted to Harbor General Hospital on 18 September 1975 with sudden onset of headache and seizures. Except for pulmonary...References1. SPARBERG M: Diagnostically confusing complications of diphenylhydantoin therapy. A review. Ann Intern Med 59:914-930, 1963 LinkGoogle Scholar2. SALTZSTEINACKERMAN SL: Lymphadenopathy induced by anticonvulsant drugs and mimicking clinically and pathologically malignant lymphoma. Cancer 12:164-182, 1959 CrossrefMedlineGoogle Scholar3. MOORE M: Pulmonary changes in hydantoin therapy. JAMA 171:1328-1333, 1959 CrossrefMedlineGoogle Scholar4. LowYAHR NM: The lack of pulmonary fibrosis in patients receiving diphenylhydantoin. JAMA 174:1201-1202, 1960 CrossrefMedlineGoogle Scholar5. HAZLETTWARDMADISON DGD: Pulmonary function loss in diphenylhydantoin therapy. Chest 66:660-664, 1974 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Harbor General Hospital Torrance, CA 90509 UCLA Medical Center Los Angeles, CA 90509 Harbor General Hospital Torrance, CA 90509 Wadsworth VA Hospital Los Angeles, CA 90073 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byIatrogenia a fármacos no contexto do Aparelho RespiratórioDrug-induced Pulmonary DisordersAntiepileptic DrugsPleural and mediastinal disorders related to drug useClinical Features and Management of Poisoning Due to PhenytoinPhenytoin-induced acute respiratory failure with pulmonary eosinophiliaPhenytoin Hepatotoxicity: A Review of the LiteratureDiphenylhydantoin-induced Lymphocytic Interstitial PneumoniaAdverse EffectsIatrogenic Thoracic Complications Induced by DrugsDrug-Induced Interstitial Lung DiseasesAcute Pulmonary Disease Caused by PhenytoinJOHN R. MICHAEL, M.D., MARILYN L. RUDIN, M.D.Diphenylhydantoin and Pulmonary FunctionAcute Hypersensitivity Pneumonitis Associated with Carbamazepine TherapyInterstitial Pneumonia from MitomycinERIC S. ORWOLL, M.D., PETER J. KIESSLING, M.D., JAMES R. PATTERSON, M.D.AnticonvulsantsPulmonary Reactions to Drugs 1 October 1976Volume 85, Issue 4Page: 475-476KeywordsEpileptic seizuresHeadachesHepatitisHepatitis AHypoxiaMorbidityThoraxToxicity Issue Published: 1 October 1976 PDF downloadLoading ...